MMF celebrates ribbon cutting on multimillion dollar mixed use residence for Elders and seniors in Selkirk
"Our goal is to provide our Elders and seniors with a home where they will feel safe and comfortable, and we believe we have done just that with this beautiful building overlooking the Red River, which holds such a symbolic and important place in our history," said Will Goodon, MMF Minister for Housing and Property Management. "We're proud to offer these beautiful, accessible residences for our Citizens, who blazed the trail for us. It's the least we can do to give back to those who have given us so much."
While the 77,900 square foot property on Eveline is the first of its kind for the MMF, it will be a template for other developments, most notably, a similar building on Henderson Highway, which will also offer a mix of affordable and market price housing options for Red River Métis Elders and seniors.
"Housing remains a critically important issue for all Canadians, which was clearly shown in the recent federal election," said David Chartrand, President of the MMF. "For our Citizens, who have at times in Canada's history been called the road allowance people, adequate, safe and accessible housing has been a long-cherished dream that was once out of reach. I know that this housing complex, along with our other housing initiatives in all Regions, is not just a place to call home, it is a source of pride and a demonstration of our strength and advancement as a Nation."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Mercanto Secures Key Listings in Quebec's New Vape Category
MONTREAL, July 7, 2025 /CNW/ - Mercanto Holdings Inc. (TSX-V: MUSH) ("Mercanto" or the "Company") is pleased to announce that it has received preliminary acceptance from the Quebec cannabis authority for three vape cartridge products under its Velada and Nordique Royale brands. This marks a significant milestone as Quebec prepares to launch its vape category — the last major provincial market in Canada to do so. Positioned at the Forefront of Canada's Last Cannabis Gold Rush Mercanto's approved products include: Cherry Blossom: A high-CBD and moderate-THC vape cartridge available in all retail stores across Quebec. Afghan Gold: A potent formulation featuring high THC and moderate CBD mirroring the Company's popular hash and hash-infused pre-roll. This SKU will also be available in all stores. Peach Sumo: A high-CBD vape offered online through the Quebec cannabis authority's e-commerce platform. With only 25 vape cartridges approved for retail stores province-wide at launch, Mercanto will hold 8% of the physical shelf space, and with 30 SKUs approved for online sales, it will command 10% of that segment. While this does not necessarily equate to 8-10% of sales, as product velocity will ultimately determine market share, it is a strong starting point that underscores the trust Mercanto has built as a supplier in Quebec over the past three years. "This is an important stepping stone for Mercanto and the culmination of our experience in Quebec," said Eric Ronsse, CEO. "Vape cartridges represent the last true gold rush in Canadian cannabis. With no entrenched incumbents in Quebec, we are as well positioned as any competitor, starting on equal footing in a market with enormous potential." Preliminary Acceptance & Next Steps While this acceptance is preliminary and conditional upon final reviews of packaging and the cartridges themselves by the Quebec cannabis authority, Mercanto does not anticipate any hurdles that would prevent these products from proceeding to full launch. Market Opportunity & Timing The Quebec cannabis authority projects that vape products will account for 11% of total cannabis sales within the first year of launch, approximately $68 million annually, with roughly 50% of this volume expected to be incremental to the market. In comparison, vape cartridges comprise about 15% of total sales in Alberta, Ontario, and British Columbia. Mercanto's vape cartridges are expected to launch across all 105 retail stores and online in November 2025 (Q2 fiscal 2026), alongside the two authorized batteries for the category, one of which the Company will supply. This synchronized rollout means Mercanto enters Quebec's vape segment with a holistic strategy: providing not only cartridges but also the essential hardware to support the entire category. "For the first time, we're entering a new category where no player holds an advantage. This levels the field and lets quality and execution speak. While our products won't be the cheapest on the shelf, and we expect to be mid-tier in pricing, they are crafted with a focus on quality, balanced formulations, and consumer experience. We're confident that's where the long-term value lies," added Ronsse. Elimination of Nursery Program Supports Scale In addition, the Quebec cannabis authority will eliminate its nursery program this October. Previously, new products were tested in roughly 25% of stores for six months before either expanding to full distribution or being delisted. Going forward, approved SKUs will be placed directly into all stores, which benefits established, trusted suppliers like Mercanto. One factor that remains unknown, however, is how frequently products will be reviewed for potential delisting and how long they will typically remain on shelves before such reviews occur. The Company currently has four products in the nursery phase and expects clarity on their status in the coming months. Outlook Mercanto believes this launch marks the beginning of a new growth chapter. With a resilient, cash-focused model and a reputation built over years of consistent supply to the Quebec cannabis authority, the Company sees the vape rollout as a catalyst that could materially impact future revenues. For More Information: Eric Ronsse President & CEO, Mercanto Holdings Inc. Forward-Looking Information Disclaimer: This press release contains forward-looking information within the meaning of applicable Canadian securities legislation. Forward-looking information typically contains statements with words such as "anticipate," "believe," "expect," "plan," "intend," "estimate," "may," "will," "should," "potential," "proposed," or similar expressions. Forward-looking statements in this document include, but are not limited to, statements regarding Mercanto Holdings Inc.'s future business plans, operations, growth potential, market conditions, product launches, and financial outlook. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Cision Canada
an hour ago
- Cision Canada
grace & stella Expands Retail Presence in Canada with Amazon, Costco, and Walmart Launches
TORONTO, July 7, 2025 /CNW/ - grace & stella, the viral beauty and self-care brand beloved for its "feel-good moments" and cult-favourite products like the iconic under-eye masks and hydrating sprays, is proud to announce a major retail expansion across Canada. This summer, Canadian consumers will be able to shop grace & stella on and in select Costco warehouses nationwide, with plans underway to enter Walmart brick-and-mortar stores later this year. Known for delivering accessible, effective, and joy-sparking skincare, grace & stella has built a loyal global following thanks to its playful branding, viral social media presence, and commitment to cruelty-free, vegan formulations. The brand's expansion into these major Canadian retail channels marks a significant milestone in its growth and mission to help more people embrace self-care as part of their daily routine. "We've always believed in the power of small rituals that spark joy," said grace & stella's Creative Director, Erin Mawhinney. "Expanding into Amazon and Costco—and soon, Walmart—makes it even easier for Canadians to experience those little feel-good moments wherever they are." Launching first on this July, Canadian customers can now access grace & stella's top-rated products with just a few clicks, complete with fast and reliable delivery. Simultaneously, select Costco stores will begin offering specially curated grace & stella bundles ideal for gifting or stocking up on self-care essentials. The rollout into Walmart locations is expected to begin later this year, with further announcements coming soon. As the brand deepens its commitment to the Canadian market, grace & stella is focused on continuing to meet its customers where they shop—both online and in store. This expansion comes at a time when consumer demand for wellness and beauty products that deliver both performance and a little daily joy is at an all-time high. With its accessible price point, playful product range, and feel-good philosophy, grace & stella is poised to become a staple in Canadian beauty routines. Visit for more updates. About grace & stella: Founded in Canada, grace & stella is a beauty brand built on the belief that skincare should be fun, feel-good, and for everyone. Best known for their best-selling under-eye masks, grace & stella is on a mission to bring a little sparkle to the everyday routine - turning skincare into a ritual worth looking forward to and sharing. Rooted in quality, transparency, and positivity, the brand creates clean, cruelty-free, and vegan products designed to help people feel great about themselves - inside and out. For grace & stella, self-care goes beyond skincare; it's about the little feel-good moments that domino into bigger feel-good moments.
Cision Canada
an hour ago
- Cision Canada
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma Français
Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /CNW/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres ® Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States. With this approval, SIR-Spheres ® is the only radioembolization therapy approved for the treatment of both metastatic colorectal cancer (mCRC) of the liver and HCC in the U.S. HCC is the most common form of liver cancer in adults in the U.S., according to the American Cancer Society. Radioembolization–commonly referred to as selective internal radiation therapy (SIRT)–with SIR-Spheres ® uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and treatment goals. "The expanded indication makes SIR-Spheres ® the only Y-90 treatment approved in the U.S. for both HCC and mCRC," said Matt Schmidt, CEO of Sirtex. "This milestone reflects our ongoing commitment to delivering flexible, personalized therapies—with multiple dose options available daily—that empowers physicians to treat patients when and where it works best." This regulatory milestone is supported by results from the DOORwaY 90 study, a prospective, multicenter, open-label clinical trial evaluating the safety and efficacy of SIR-Spheres ® in treating HCC. The study enrolled 100 patients across 18 U.S. centers, with 65 patients included in the interim primary efficacy cohort. DOORwaY 90 met its prespecified co-primary endpoints, demonstrating a best overall response rate (ORR) of 98.5% as assessed by independent central review. All evaluable patients demonstrated a response, indicating a 100% local tumor control rate. Additionally, the median duration of response (DoR) exceeded 300 days. These findings highlight SIR-Spheres ® as a highly effective liver-directed therapy with a favorable safety profile. "This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results," said Dr. Armeen Mahvash, Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY 90 Study. "This will give multidisciplinary care teams the confidence to recommend SIR-Spheres ® for HCC treatment." For more information and details on how to incorporate SIR-Spheres ® into your practice, please contact Sirtex at [email protected]. About SIR-Spheres ® SIR-Spheres ® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child-Pugh A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Caution: Federal (USA) law restricts this device for sale by or on the order of a physician. Consult the Instructions for Use ( for a complete listing of indications, contraindications, side effects, warnings and precautions. About Sirtex Sirtex Medical is a global healthcare company focused on advancing minimally invasive, liver-directed cancer and embolization therapies. With offices in the U.S., Australia, Europe, and Asia, Sirtex delivers innovative interventional oncology and embolization solutions to physicians and patients worldwide. The company's lead product, SIR-Spheres ® Y-90 resin microspheres, is now the only FDA approved product in the United States indicated for both the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). For more information, visit APM-US-010-06-25
